| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 26, 2020“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies
Redmond, Wash., USA, and New York 26 May 2020 A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic...
-
May 7, 2020- Rapidly expanding support for the Alliance is increasing donations of convalescent plasma to begin clinical production, while NIH collaboration confirms clinical trial approach
Osaka, JAPAN, and King of Prussia, PA, USA – 7 May 2020 – The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a...
-
Apr 21, 2020Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method
PHILADELPHIA, PA – April 21, 2020 – Global biotherapeutics leader CSL Behring today announced that a clinical study examining faster infusion rates and higher volumes than currently approved...
-
Apr 8, 2020COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer
King of Prussia, Pa. and Sioux Falls, S.D. 08 Apr 2020 Global biotherapeutics leader, CSL Behring and innovative human antibody development company SAB Biotherapeutics (SAB) announced today their...
-
Apr 6, 2020Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Osaka, JAPAN, and King of Prussia, PA, USA 06 Apr 2020 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company...